<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33226425</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>186</StartPage><EndPage>196</EndPage><MedlinePgn>186-196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.4300</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor nervous system. Clinical studies have demonstrated cortical and spinal motor neuron hyperexcitability using transcranial magnetic stimulation and threshold tracking nerve conduction studies, respectively, although metrics of excitability have not been used as pharmacodynamic biomarkers in multi-site clinical trials.</AbstractText><AbstractText Label="OBJECTIVE">To ascertain whether ezogabine decreases cortical and spinal motor neuron excitability in ALS.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This double-blind, placebo-controlled phase 2 randomized clinical trial sought consent from eligible participants from November 3, 2015, to November 9, 2017, and was conducted at 12 US sites within the Northeast ALS Consortium. Participants were randomized in equal numbers to a higher or lower dose of ezogabine or to an identical matched placebo, and they completed in-person visits at screening, baseline, week 6, and week 8 for clinical assessment and neurophysiological measurements.</AbstractText><AbstractText Label="INTERVENTIONS">Participants were randomized to receive 600 mg/d or 900 mg/d of ezogabine or a matched placebo for 10 weeks.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was change in short-interval intracortical inhibition (SICI; SICI-1 was used in analysis to reflect stronger inhibition from an increase in amplitude) from pretreatment mean at screening and baseline to the full-dose treatment mean at weeks 6 and 8. The secondary outcomes included levels of cortical motor neuron excitability (including resting motor threshold) measured by transcranial magnetic stimulation and spinal motor neuron excitability (including strength-duration time constant) measured by threshold tracking nerve conduction studies.</AbstractText><AbstractText Label="RESULTS">A total of 65 participants were randomized to placebo (23), 600 mg/d of ezogabine (23), and 900 mg/d of ezogabine (19 participants); 45 were men (69.2%) and the mean (SD) age was 58.3 (8.8) years. The SICI-1 increased by 53% (mean ratio, 1.53; 95% CI, 1.12-2.09; P&#x2009;=&#x2009;.009) in the 900-mg/d ezogabine group vs placebo group. The SICI-1 did not change in the 600-mg/d ezogabine group vs placebo group (mean ratio, 1.15; 95% CI, 0.87-1.52; P&#x2009;=&#x2009;.31). The resting motor threshold increased in the 600-mg/d ezogabine group vs placebo group (mean ratio, 4.61; 95% CI, 0.21-9.01; P&#x2009;=&#x2009;.04) but not in the 900-mg/d ezogabine group vs placebo group (mean ratio, 1.95; 95% CI, -2.64 to 6.54; P&#x2009;=&#x2009;.40). Ezogabine caused a dose-dependent decrease in excitability by several other metrics, including strength-duration time constant in the 900-mg/d ezogabine group vs placebo group (mean ratio, 0.73; 95% CI, 0.60 to 0.87; P&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Ezogabine decreased cortical and spinal motor neuron excitability in participants with ALS, suggesting that such neurophysiological metrics may be used as pharmacodynamic biomarkers in multisite clinical trials.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT02450552.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wainger</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care &amp; Pain Medicine, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Cambridge.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIlduff</LastName><ForeName>Courtney E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkove</LastName><ForeName>Seward B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Dale J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital for Special Surgery, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivner</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Augusta University Medical Center, Augusta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauricio</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pothier</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassis</LastName><ForeName>Sylvia Baedorf</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La</LastName><ForeName>Thuong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evora</LastName><ForeName>Armineuza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klements</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurtado</LastName><ForeName>Aura</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Joao D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celnik</LastName><ForeName>Pablo A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhry</LastName><ForeName>Vinay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gable</LastName><ForeName>Karissa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juel</LastName><ForeName>Vern C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phielipp</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marei</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital for Special Surgery, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenquist</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Augusta University Medical Center, Augusta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meehan</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Kinesiology, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Divpreet</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiskinis</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolf</LastName><ForeName>Clifford J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston Children's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Cambridge.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davila-Perez</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camprodon</LastName><ForeName>Joan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual-Leone</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Marcus Institute and Center for Memory Health, Hebrew SeniorLife, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Guttmann, Universitat Autonoma, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>The Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02450552</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>DP2 NS106664</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010655">Phenylenediamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12G01I6BBU</RegistryNumber><NameOfSubstance UI="C101866">ezogabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010655" MajorTopicYN="N">Phenylenediamines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Wainger is a New York Stem Cell Foundation-Robertson Investigator; reported receiving grants from the National Institutes of Health (NIH; 1DP2-NS10664), the ALS Association, GlaxoSmithKline, Harvard Stem Cell Institute, Target ALS, ALS Finding a Cure, MassLifeSciences, Revalesio, AITherapeutics, and Sanofi during the conduct of the study; personal fees from Amgen, Quralis, Apic Biosciences, Q-State Biosciences outside the submitted work; and had patent US9517223B2 issued for use of potassium channel openers in neurodegenerative diseases. Dr Macklin reported receiving institutional support from grants from Acorda Therapeutics Grant, Amylyx Pharmaceuticals Grant, the Mitsubishi Tanabe Pharmaceutical America, Biohaven Pharmaceuticals Grant, Clene Nanomedicine Grant, Prilenia Therapeutics Grant, and Ra Pharmaceuticals; personal fees from serving as a Biogen Steering Committee member, a Stoparkinson Healthcare LLC Steering Committee member, an Acorda Therapeutics data safety monitoring board member, a Novartis Pharmaceuticals data safety monitoring board member, a Takeda Pharmaceuticals data safety monitoring board member, a Cerevance advisory board member, an Inventram advisory board member, and a Partners Therapeutics advisory board member; personal fees from serving as consultant to Lavin Consulting and Myolex Inc. outside the submitted work. Dr Vucic reported receiving consultancy fees from Biogen Idec Australia and Merck Serono Pty Ltd Australia. Dr Paganoni reported receiving grants from the ALS Association during the conduct of the study; grants from ALS Association, ALS Finding a Cure, the Spastic Paraplegia Foundation, the Salah Foundation, the Muscular Dystrophy Association, the American Academy of Neurology, Amylyx, Revalesio, Ra Pharma, Biohaven, Clene, and Prilenia; and personal fees from Orion outside the submitted work. Dr Maragakis reported serving as consultant to Orion, Apellis Pharmaceuticals, Seneca Biopharmaceuticals, Inc., Amylyx Pharmaceuticals, and Orphazyme. Dr Bedlack reported receiving personal fees from Biogen, Brainstorm Cell, Alexion Pharmaceuticals, the ALS Assocation, Mallinkrodt, Amylyx, MT Pharma; grants from Orion; and personal fees from New Biotic, and Woolsey Pharma outside the submitted work. Dr Goyal reported receiving research support from Brainstorm Cell Therapeutics, Cytokinetics, Fulcrum, Kezar, Octapharma, Orion, and Orphazyme; serving on Advisory Boards for Acceleron, Alexion Pharmaceuticals, Argenx, CSL Behring, MT Pharma, Sanofi Genzyme, Sarepta, and UCB; serving on the speaker&#x2019;s bureau for CSL Behring. Dr Rivner reported grants from Alexion Pharmaceuticals, Catalyst Pharmaceuticals, Analixis, Medicinova, UBC, Apellis, Momenta, Ra, Takeda, Seikagaku, and Orion outside the submitted work; and personal fees from Alexion Pharmaceuticals and Allergan Pharmaceuticals. Dr Goutman reported receiving grants from the ALS Association during the conduct of the study; grants from NIH/National Institute of Environmental Health Sciences, the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, and Target ALS; and personal fees from Biogen scientific advisory board, ITF Pharma scientific advisory board, and Watermark Research Partners data safety monitoring board service outside the submitted work. Dr Baloh reported receiving personal fees from Mitochondria in Motion and Acurastem outside the submitted work. Dr Simmons reported receiving personal fees from Amylyx, grants and personal fees from Biogen and Biohaven, and personal fees from Cytokinetics outside the submitted work. Ms Hall reported receiving grants from the ALS Association. Dr Oskarsson reported receiving personal fees from Medicinova, Mitsubishi, Biogen, Columbia University/Tsumura Inc.; and grants from Biogen, Mitsubishi, Medicinova, Genentech, Cytokinetics. Dr Lewis reported receiving personal fees from CSL Behring, Pfizer, Argenx, Momenta, Pharnext, Sanofi, Annexon, Takeda Pharmaceuticals, Akcea, and Alnylam outside the submitted work. Dr Kiskinis is a Les Turner ALS Research Center Investigator and a New York Stem Cell Foundation-Robertson Investigator and had patent US9517223B2 issued for use of potassium channel openers in neurodegenerative diseases. Dr Woolf reported receiving grants from MassLifeSciences, TargetALS, and GSK during the conduct of the study; being a co-founder of Quralis; and had patent US9517223B2 issued for use of potassium channel openers in neurodegenerative diseases. Dr Eggan reported receiving grants from GlaxoSmithKline; personal fees, consulting fees, and founder equity from Quralis, Q-State Biosciences, and Enclear Therapeutics; stock grant from BioMarin Stock grant outside the submitted work; and had patent US9517223B2 issued for use of potassium channel openers in neurodegenerative diseases. Dr Weiss reported receiving grants from the ALS Association and ALS Finding a Cure; personal fees from Biogen, Ra Pharmaceuticals, Argenx, NuFactor, and Mitsubishi Tanabe Pharma outside the submitted work. Dr Berry reported receiving personal fees from Biogen, Clene Nanomedicine, and Alexion Pharmaceuticals; grants from MT Pharma of America, Brainstorm Cell Therapeutics, Genentech, Amylyx Therapeutics, Alexion Pharmaceuticals, Biogen, Clene Nanomedicine, ALS One, ALS Finding A Cure, the Muscular Dystrophy Association, and the ALS Association outside the submitted work. Dr Camprodon reported receiving stocks from Apex Neuroscience outside the submitted work. Dr Pascual-Leone reported receiving personal fees from Starlab, Neuroelectrics, and Magstim outside the submitted work; and had a patent to Integration TMS with EEG and MRI issued. Dr Kiernan reported service as Editor-in-Chief of the <i>Journal of Neurology</i>, <i>Neurosurgery &amp; Psychiatry</i> (BMJ Publishers); and receiving a grant from the National Health and Medical Research Council of Australia. Dr Shefner reported receiving grants from the ALS Association during the conduct of the study; grants and personal fees from Cytokinetics, Brainstorm, Amylyx, Biogen, and MT Pharma America; and personal fees from Neurosense, Immunity Pharma, Sanofi, Apic Bio, Avexis, Orphazyme; grants from Alexion Pharmaceuticals. Dr Atassi is a full-time employee of Sanofi-Genzyme. Dr Cudkowicz reported serving as an advisory board chairperson for Lily, and as a consultant to Biogen, Pharmnext, Treeway, Avexis, Revalasio, Aclipse, Mt Pharma, Biohaven, Sunovian, Anelixis, Cytokinetics, ALS Pharma, RRD International, Disarm, and Immunity Pharm outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>23</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33226425</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pii">2773459</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-172. doi:10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(Pt 6):1540-1550. doi:10.1093/brain/awn071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn071</ArticleId><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair IP, Williams KL, Warraich ST, et al. . FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry. 2010;81(6):639-645. doi:10.1136/jnnp.2009.194399</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.194399</ArticleId><ArticleId IdType="pubmed">19965854</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015;14(5):478-484. doi:10.1016/S1474-4422(15)00014-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00014-9</ArticleId><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogyoros I, Kiernan MC, Burke D, Bostock H. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain. 1998;121(Pt 5):851-859. doi:10.1093/brain/121.5.851</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/121.5.851</ArticleId><ArticleId IdType="pubmed">9619189</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Howells J, Nicholson GA, Kiernan MC, Vucic S. Axonal ion channel dysfunction in c9orf72 familial amyotrophic lateral sclerosis. JAMA Neurol. 2015;72(1):49-57. doi:10.1001/jamaneurol.2014.2940</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2940</ArticleId><ArticleId IdType="pubmed">25384182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Shibuya K, Sato Y, et al. . Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734-738. doi:10.1136/jnnp-2011-301782</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301782</ArticleId><ArticleId IdType="pubmed">22566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Park SB, Geevasinga N, et al. . Motor cortical function determines prognosis in sporadic ALS. Neurology. 2016;87(5):513-520. doi:10.1212/WNL.0000000000002912</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002912</ArticleId><ArticleId IdType="pubmed">27402895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sances S, Bruijn LI, Chandran S, et al. . Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat Neurosci. 2016;19(4):542-553. doi:10.1038/nn.4273</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4273</ArticleId><ArticleId IdType="pmc">PMC5015775</ArticleId><ArticleId IdType="pubmed">27021939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Kiskinis E, Mellin C, et al. . Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1-11. doi:10.1016/j.celrep.2014.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.019</ArticleId><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Moakley D, Koh J, Pereira JD, et al. . Pharmacological profiling of purified human stem cell-derived and primary mouse motor neurons. Sci Rep. 2019;9(1):10835. doi:10.1038/s41598-019-47203-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47203-7</ArticleId><ArticleId IdType="pmc">PMC6658502</ArticleId><ArticleId IdType="pubmed">31346219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E, Sandoe J, Williams LA, et al. . Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14(6):781-795. doi:10.1016/j.stem.2014.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, et al. . Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313-325. doi:10.1038/nm.4490</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodie MJ, Lerche H, Gil-Nagel A, et al. ; RESTORE 2 Study Group . Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75(20):1817-1824. doi:10.1212/WNL.0b013e3181fd6170</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181fd6170</ArticleId><ArticleId IdType="pubmed">20944074</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lazzaro V, Rothwell J, Capogna M. Noninvasive stimulation of the human brain: activation of multiple cortical circuits. Neuroscientist. 2018;24(3):246-260. doi:10.1177/1073858417717660</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858417717660</ArticleId><ArticleId IdType="pubmed">28659070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol. 2003;2(3):145-156. doi:10.1016/S1474-4422(03)00321-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(03)00321-1</ArticleId><ArticleId IdType="pubmed">12849236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000;23(3):399-409. doi:10.1002/(SICI)1097-4598(200003)23:3&lt;399::AID-MUS12&gt;3.0.CO;2-G</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(200003)23:3&lt;399::AID-MUS12&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pubmed">10679717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Bostock H, Park SB, et al. . Measurement of axonal excitability: consensus guidelines. Clin Neurophysiol. 2020;131(1):308-323. doi:10.1016/j.clinph.2019.07.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.07.023</ArticleId><ArticleId IdType="pubmed">31471200</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan K, Kunesch E, Benecke R, Classen J. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann Neurol. 2001;49(4):536-539. doi:10.1002/ana.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.107</ArticleId><ArticleId IdType="pubmed">11310635</ArticleId></ArticleIdList></Reference><Reference><Citation>Caramia MD, Palmieri MG, Desiato MT, et al. . Pharmacologic reversal of cortical hyperexcitability in patients with ALS. Neurology. 2000;54(1):58-64. doi:10.1212/WNL.54.1.58</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.54.1.58</ArticleId><ArticleId IdType="pubmed">10636126</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang K-Y;, Zeger SL Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhy&#x101;: Indian J Stat Ser B (1960-2002). 2000;62(1):134-148.</Citation></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265-267. doi:10.1212/01.wnl.0000194316.91908.8a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. ; WFN Research Group On ALS/MND . A revision of the El Escorial criteria&#x2014;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-292. doi:10.3109/21678421.2015.1049183</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, et al. . Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601-609. doi:10.1016/j.nbd.2003.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Watson ML, Simionescu L, et al. . Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology. 2011;77(3):235-241. doi:10.1212/WNL.0b013e318225aabf</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318225aabf</ArticleId><ArticleId IdType="pmc">PMC3136054</ArticleId><ArticleId IdType="pubmed">21676915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciliberto MA, Weisenberg JL, Wong M. Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug Healthc Patient Saf. 2012;4:81-86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413039</ArticleId><ArticleId IdType="pubmed">22888276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman M, Cudkowicz M, Zinman L. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. Curr Opin Neurol. 2012;25(6):735-742. doi:10.1097/WCO.0b013e32835a309d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32835a309d</ArticleId><ArticleId IdType="pubmed">23160423</ArticleId></ArticleIdList></Reference><Reference><Citation>Davila-P&#xe9;rez P, Jannati A, Fried PJ, Cudeiro Mazaira J, Pascual-Leone A. The effects of waveform and current direction on the efficacy and test-retest reliability of transcranial magnetic stimulation. Neuroscience. 2018;393:97-109. doi:10.1016/j.neuroscience.2018.09.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.09.044</ArticleId><ArticleId IdType="pmc">PMC6291364</ArticleId><ArticleId IdType="pubmed">30300705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermsen AM, Haag A, Duddek C, et al. . Test-retest reliability of single and paired pulse transcranial magnetic stimulation parameters in healthy subjects. J Neurol Sci. 2016;362:209-216. doi:10.1016/j.jns.2016.01.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.01.039</ArticleId><ArticleId IdType="pubmed">26944150</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanz O, Bageac D, Braun L, Traynor BJ, Lehky TJ, Floeter MK. Cortical hyperexcitability in patients with C9ORF72 mutations: relationship to phenotype. Muscle Nerve. 2016;54(2):264-269. doi:10.1002/mus.25047</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25047</ArticleId><ArticleId IdType="pmc">PMC4940214</ArticleId><ArticleId IdType="pubmed">26799151</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Fifita JA, Vucic S, et al. . Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry. 2013;84(8):931-935. doi:10.1136/jnnp-2012-304529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304529</ArticleId><ArticleId IdType="pubmed">23463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2015;126(4):803-809. doi:10.1016/j.clinph.2014.04.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2014.04.023</ArticleId><ArticleId IdType="pubmed">25227219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanette G, Tamburin S, Manganotti P, Refatti N, Forgione A, Rizzuto N. Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(12):1723-1728. doi:10.1007/s00415-002-0926-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-002-0926-7</ArticleId><ArticleId IdType="pubmed">12529797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chervyakov AV, Bakulin IS, Savitskaya NG, et al. . Navigated transcranial magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve. 2015;51(1):125-131. doi:10.1002/mus.24345</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24345</ArticleId><ArticleId IdType="pubmed">25049055</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills KR, Nithi KA. Corticomotor threshold to magnetic stimulation: normal values and repeatability. Muscle Nerve. 1997;20(5):570-576. doi:10.1002/(SICI)1097-4598(199705)20:5&lt;570::AID-MUS5&gt;3.0.CO;2-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199705)20:5&lt;570::AID-MUS5&gt;3.0.CO;2-6</ArticleId><ArticleId IdType="pubmed">9140363</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006;117(7):1458-1466. doi:10.1016/j.clinph.2006.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2006.04.016</ArticleId><ArticleId IdType="pubmed">16759905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain. 2000;123(Pt 12):2542-2551. doi:10.1093/brain/123.12.2542</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.12.2542</ArticleId><ArticleId IdType="pubmed">11099455</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):384-393. doi:10.1007/s13311-014-0331-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0331-9</ArticleId><ArticleId IdType="pmc">PMC4404434</ArticleId><ArticleId IdType="pubmed">25582382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromberg MB, Brownell AA. Motor unit number estimation in the assessment of performance and function in motor neuron disease. Phys Med Rehabil Clin N Am. 2008;19(3):509-532, ix. doi:10.1016/j.pmr.2008.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmr.2008.02.006</ArticleId><ArticleId IdType="pubmed">18625413</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Cole T, Wegener AJ, et al. . Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558-3567. doi:10.1172/JCI99081</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci. 2010;33(1):409-440. doi:10.1146/annurev.neuro.051508.135722</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.051508.135722</ArticleId><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T, McAvoy K, Russell K, et al. . Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. EMBO Mol Med. 2019;11(2):e9423. doi:10.15252/emmm.201809423</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201809423</ArticleId><ArticleId IdType="pmc">PMC6365928</ArticleId><ArticleId IdType="pubmed">30617154</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Tank EM, Miguez R, et al. . Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J Clin Invest. 2020;130(3):1139-1155. doi:10.1172/JCI130988</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130988</ArticleId><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci. 2000;12(10):3567-3574. doi:10.1046/j.1460-9568.2000.00242.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2000.00242.x</ArticleId><ArticleId IdType="pubmed">11029626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bean BP The action potential in mammalian central neurons. Nat Rev Neurosci. 2007;8(6):451-465. doi:10.1038/nrn2148</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2148</ArticleId><ArticleId IdType="pubmed">17514198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk MO, Heuberger JAAC, Sleutjes BTHM, et al. . Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, crossover trial. Clin Pharmacol Ther. 2018;104(6):1136-1145. doi:10.1002/cpt.1096</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1096</ArticleId><ArticleId IdType="pubmed">29672831</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Ng K, et al. . Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7-8):580-588. doi:10.1080/21678421.2016.1188961</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1188961</ArticleId><ArticleId IdType="pubmed">27249331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>